Avadim to Introduce Breakthrough Topical Anti-Spasmodic Sports Medicine Technology
Asheville, NC (May 24, 2016) – Avadim Technologies, Inc. (“Avadim”), a life sciences company delivering Pathogenesis Based Therapies (“PBTs”), which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue, announced today that [pH]UEL 5.0™, its non-toxic topical anti-spasmodic, will be showcased at the 67th National Athletic Trainers Association (“NATA”) Clinical Symposia & AT Expo, in Baltimore, MD on June 22-25, 2016.
According to NATA, this year’s Clinical Symposia will bring more athletic trainers under one roof than any other tradeshow. It is the world’s premier exhibition in sports medicine, with over 350 exhibitors and thousands of athletic trainers converging for a 3-day marketplace of products, education and services to outfit training facilities.
Stephen Woody, Chairman and CEO of Avadim, stated, “Sports medicine continues to search for safe, effective and non-systemic solutions for Exercise-Associated Muscle Cramps (“EMAC”) and associated tightness and soreness, that have been shown to increase the risk of athletic injury and prevent optimal performance. [pH]UEL 5.0’s™ patented low pH formulation has been shown to significantly reduce the incidence of EMAC and associated symptoms in the elite athlete.”
Mr. Woody continued, “Currently, our [pH]UEL 5.0’s™ patented therapies and protocols are being utilized and evaluated by over 500 professional, university and high school athletic teams throughout the United States including the St. Louis Blues, Washington Capitals, Tampa Bay Rays, University of Florida, Florida State, and Duke. As with our other Pathogenesis Based Therapies, we are excited about [pH]UEL 5.0’s ability to fill this major global gap in sports medicine.”
Scientific evidence suggests that maintaining and lowering the pH of the body’s largest organ, the skin, increases oxygen availability and uptake. Oxygen availability is a cornerstone for recovery and optimal performance. [pH]UEL 5.0 has been clinically formulated to lower the pH of the skin.
The NATA Clinical Symposia & AT Expo will be held at Baltimore Convention Center in Baltimore, MD on June 22-25, 2016. Athletic trainers are encouraged to visit [pH]UEL 5.0 at booth number 5113.
About [pH]UEL 5.0™:
[pH]UEL 5.0™, a division of Avadim Technologies Inc., is committed to making a difference by bringing highly differentiated technologies into the health and athletic arenas. [pH]UEL 5.0™ is a topical technology, formulated for the most difficult muscle integrity issues including muscle performance, muscle tightness, muscle recovery, muscle cramps, and flexibility. For more information, visit www.phuel5.com
About Avadim Technologies, Inc.:
Avadim Technologies, Inc. is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.
For more information on Avadim, visit www.avadimtechnologies.com
Avadim Technologies Inc. Contacts:
Joe McGuire, Chief Financial Officer
David Fann, President